Tolerance in the Post-Vioxx Era
This article was originally published in RPM Report
Executive Summary
The phrase post "post-Vioxx environment" is the cliché du jour in pharma: the simple way to explain any setback in drug development. The question is how much time will Wall Street allow a company while it works to clear the regulatory hurdle. Palatin Technologies' NeutroSpec is a good case example.